Answers are grounded in this paper and cite their sources.
Resistance to trastuzumab deruxtecan (T-DXd) limits treatment options for HER2-mutant non-small cell lung cancer (NSCLC). We investigated resistance mechanisms and zongertinib activity using T-DXd-resistant cells, patient tumor specimens, and patient-derived organoids (PDOs). Comparative analyses identified upregulation of ATP-binding cassette transporter G2 (ABCG2) in resistant cells. ABCG2 expression increased after T-DXd treatment in five of six paired tumor specimens. ABCG2 knockdown enhanced T-DXd sensitivity in resistant cells, while pharmacological inhibition enhanced sensitivity in resistant PDOs. HER2 signaling remained active in resistant models, and zongertinib inhibited HER2 phosphorylation and organoid growth. Tumor shrinkage was also observed in the corresponding patients treated with zongertinib. These findings provide patient-linked evidence implicating ABCG2 in acquired T-DXd resistance and suggest that HER2 signaling remains therapeutically targetable with zongertinib after T-DXd resistance in HER2-mutant NSCLC.
No takes yet. Share an insight, caveat, or question.
Kawanaka et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: